Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference

Pui, 2006, Treatment of acute lymphoblastic leukaemia, N. Engl. J. Med., 354, 166, 10.1056/NEJMra052603 Moghrabi, 2007, Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukaemia, Blood, 109, 896, 10.1182/blood-2006-06-027714 Moricke, 2008, Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95, Blood, 111, 4477, 10.1182/blood-2007-09-112920 Conter, 2000, Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982–1995, Leukemia, 14, 2196, 10.1038/sj.leu.2401963 Pession, 2005, for: Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP); Dutch Childhood Oncology Group (DCOG); Hungarian Pediatric Hematology Oncology Group (HPOG). Long term results of a randomized trial on extended use of high dose l-asparaginase for standard risk childhood acute lymphoblastic leukemia, J. Clin. Oncol., 23, 7161, 10.1200/JCO.2005.11.411 Henze, 1991, Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): a relapse study of the BFM group, Blood, 78, 1166, 10.1182/blood.V78.5.1166.bloodjournal7851166 Paganin, 2008, Minimal residual disease is an important predictive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leukemia, Leukemia, 22, 2193, 10.1038/leu.2008.227 Chessells, 2003, Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia, Br. J. Haematol., 123, 396, 10.1046/j.1365-2141.2003.04584.x Copelan, 2006, Hematopoietic stem cell transplantation, N. Engl. J. Med., 354, 1813, 10.1056/NEJMra052638 Gatti, 1968, Immunological reconstitution of sex linked lymphopenic immunological deficiency, Lancet, 2, 1366, 10.1016/S0140-6736(68)92673-1 Bach, 1968, Bone marrow transplantation in a patient with the Wiskott–Aldrich syndrome, Lancet, 2, 1364, 10.1016/S0140-6736(68)92672-X Grewal, 2003, Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?, Blood, 101, 4233, 10.1182/blood-2002-08-2510 Rocha, 2008, Searching for alternative hematopoietic stem cell donors for pediatric patients, Bone Marrow Transplant., 41, 207, 10.1038/sj.bmt.1705963 Bachar-Lustig, 1995, Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice, Nat. Med., 1, 1268, 10.1038/nm1295-1268 Aversa, 1998, Treatment of high risk acute leukaemia with T-depleted stem cells from related donors with one fully mismatched HLA haplotype, N. Eng. J. Med., 339, 1186, 10.1056/NEJM199810223391702 Aversa, 2005, Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse, J. Clin. Oncol., 23, 3447, 10.1200/JCO.2005.09.117 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Lang, 2004, Long-term outcome after haploidentical stem cell transplantation in children blood, Cell Mol. Dis., 33, 281, 10.1016/j.bcmd.2004.08.017 Marks, 2006, Haploidentical stem cell transplantation for children with acute leukaemia, Br. J. Haematol., 134, 196, 10.1111/j.1365-2141.2006.06140.x Stern, 2008, Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor, Blood, 112, 2990, 10.1182/blood-2008-01-135285 Ball, 2005, Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation, Bone Marrow Transplant., 35, S35, 10.1038/sj.bmt.1704842 Lilleri, 2009, Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation, J. Infect. Dis., 199, 829, 10.1086/597123 Perruccio, 2005, Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation, Blood, 106, 4397, 10.1182/blood-2005-05-1775 Comoli, 2007, Preemptive treatment of EBV-related post-transplant lymphoproliferative disorders after pediatric haploidentical stem cell transplantation, Am. J. Transplant., 7, 1648, 10.1111/j.1600-6143.2007.01823.x Feuchtinger, 2006, Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation, Br. J. Haematol., 134, 64, 10.1111/j.1365-2141.2006.06108.x Ball, 2007, Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation, Blood, 110, 2764, 10.1182/blood-2007-04-087056 Spaggiari, 2006, Mesenchymal stem cell (MSC)/natural killer (NK) cell interactions: evidence that activated NK cells are capable of killing MSC while MSC can inhibit IL-2-induced NK cell proliferation, Blood, 107, 1484, 10.1182/blood-2005-07-2775 Spaggiari, 2008, Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2, Blood, 111, 1327, 10.1182/blood-2007-02-074997 Ljunggren, 1990, In search of the “missing self”. MHC molecules and NK cell recognition, Immunol. Today, 11, 237, 10.1016/0167-5699(90)90097-S Bennet, 1987, Biology and genetics of hybrid resistance, Adv. Immunol., 41, 333, 10.1016/S0065-2776(08)60034-6 Moretta, 1990, A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function, J. Exp. Med., 171, 695, 10.1084/jem.171.3.695 Moretta, 1990, Identification of four subset of human CD3-CD16+ NK cells by the expression of clonally distributed functional surface molecules. Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition, J. Exp. Med., 172, 1589, 10.1084/jem.172.6.1589 Moretta, 1993, p58 molecules as putative receptors for MHC class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities, J. Exp. Med., 178, 597, 10.1084/jem.178.2.597 Wagtmann, 1995, Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intracellular domains, Immunity, 2, 439, 10.1016/1074-7613(95)90025-X Colonna, 1995, Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells, Science, 268, 405, 10.1126/science.7716543 Litwin, 1994, NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules, J. Exp. Med., 180, 537, 10.1084/jem.180.2.537 Vitale, 1996, Physical and functional independency of p70 and p58 NK cell receptors for HLA-class I. Their role in the definition of different groups of alloreactive NK cell clones, Proc. Natl. Acad. Sci. U. S. A., 93, 1453, 10.1073/pnas.93.4.1453 Pende, 1996, The Natural Killer cell receptor specific for HLA.A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140 kD disulphide-linked dimer, J. Exp. Med., 184, 505, 10.1084/jem.184.2.505 Dohring, 1996, Human natural killer cell inhibitory receptors bind to HLA class I molecules, Eur. J. Immunol., 26, 365, 10.1002/eji.1830260215 Moretta, 1995, Existence of both inhibitory (p58) and activatory (p50) receptors for HLA.C molecules in human natural killer cells, J. Exp. Med., 182, 875, 10.1084/jem.182.3.875 Biassoni, 1996, The HLA.C specific “activatory” and “inhibitory” natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions, J. Exp. Med., 183, 645, 10.1084/jem.183.2.645 Bottino, 1996, A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation, Eur. J. Immunol., 26, 1816, 10.1002/eji.1830260823 Moretta, 1996, Receptors for HLA-class I molecules in human natural killer cells, Annu. Rev. Immunol., 14, 619, 10.1146/annurev.immunol.14.1.619 Moretta, 2002, What is a natural killer cell?, Nat. Immunol., 3, 6, 10.1038/ni0102-6 Lanier, 1998, NK cell receptors, Annu. Rev. Immunol., 16, 359, 10.1146/annurev.immunol.16.1.359 Long, 1999, Regulation of immune responses through inhibitory receptors, Annu. Rev. Immunol., 17, 875, 10.1146/annurev.immunol.17.1.875 Lopez-Botet, 2000, NK cell recognition of non-classical HLA class I molecules, Semin. Immunol., 12, 109, 10.1006/smim.2000.0213 Mingari, 1995, Cytolytic T lymphocytes displaying natural killer (NK)-like activity. Expression of NK-related functional receptors fir HLA-class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production, Int. Immunol., 7, 697, 10.1093/intimm/7.4.697 Moretta, 2003, NK-CTL, a novel HLA-E-restricted T cell subset, Trends Immunol., 24, 136, 10.1016/S1471-4906(03)00031-0 Vivier, 2004, Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future, Nat. Rev. Immunol., 4, 190, 10.1038/nri1306 Moretta, 2008, Human NK cells: from HLA class I-specific Ig-like receptors to the therapy of acute leukemias, Immunol. Rev., 224, 58, 10.1111/j.1600-065X.2008.00651.x Velardi, 2002, NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol., 23, 438, 10.1016/S1471-4906(02)02284-6 Sivori, 2003, IL21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors, Eur. J. Immunol., 33, 3439, 10.1002/eji.200324533 Shilling, 2002, Genetic control of human NK cell repertoire, J. Immunol., 169, 239, 10.4049/jimmunol.169.1.239 Shilling, 2003, Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation, Blood, 101, 3730, 10.1182/blood-2002-08-2568 Ciccone, 1992, Involvement of HLA class I alleles in NK cell specific function: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2), J. Exp. Med., 176, 963, 10.1084/jem.176.4.963 Ciccone, 1994, Self Class I molecules protect normal cells from lysis mediated by autologous natural killer cells, Eur. J. Immunol., 24, 1003, 10.1002/eji.1830240434 Costello, 2002, Defective expression and function of natural killer cell triggering receptors in patients with acute myeloid leukemia, Blood, 99, 3661, 10.1182/blood.V99.10.3661 Bottino, 2005, Cellular ligands for activating NK receptors, Trends Immunol., 26, 221, 10.1016/j.it.2005.02.007 Pende, 2005, Analysis of the receptor–ligand interactions in the NK-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias. Evidence for the involvement of the poliovirus receptor (CD155) and Nectin-2 (CD112), Blood, 105, 2066, 10.1182/blood-2004-09-3548 Aversa, 1994, Successful engraftment of T-depleted haploidentical “three-loci” incompatible transplants in leukaemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum, Blood, 84, 3948, 10.1182/blood.V84.11.3948.bloodjournal84113948 Shlomchik, 1999, Prevention of graft versus host disease by inactivation of host antigen-presenting cells, Science, 285, 412, 10.1126/science.285.5426.412 Della Chiesa, 2003, The natural killer cell mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer IG-like receptors, Eur. J. Immunol., 33, 1657, 10.1002/eji.200323986 Pende, 2009, Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity, Blood, 113, 3119, 10.1182/blood-2008-06-164103 Vitale, 2004, Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2, Int. Immunol., 16, 1459, 10.1093/intimm/dxh147